the aid library

LIST OPTIONS

Filter

2340

Sort by:

Direction:

Download (187)

View PDF (238)

Traumatische Erlebnisse bei Kindern: Diagnostik und Psycho-Edukation

Regula Buchli; Carmen de Witt-Amrein; Fabienne Heiniger Erziehungsdirektion Kanton Bern, Amt für Kindergarten, Volksschule und Beratung (AKVB) (2017) C2

Die aktuelle weltpolitische Lage führt dazu, dass immer mehr potentiell traumatisierte Kinder der Unterstützung von Fachleuten – auch in der psychologischen Grundversorgung - bedürfen. Traumata können bei Kindern aber auch durch Hospitalisationen und damit verbundene medizinische Eingriffe, Un... more

Download (1107)

View PDF (1600)

LA PRISE EN CHARGE DU PALUDISME GRAVE - Troisième Édition

World Health Organisation (WHO) (2013) C_WHO

Le présent guide pratique de prise en charge du paludisme grave et de ses complications est la troisième révision et actualisation de l'ouvrage. Il est destiné prioritairement aux professionnels de santé; travaillant dans des hôpitaux ou des centres de santé disposant de structures d'hospital... more

Download (151)

View PDF (143)

Mauritius National Action Plan on Antimicrobial Resistance 2017-2021

Ministry of Health and Quality of Life Mauritius (2017) C2

Antimicrobial resistance has become a serious public health threat for effective treatment of an ever increasing range of infections caused by bacteria, parasites, viruses and fungi. When infections can no longer be treated by first-line antibiotics, other antibiotics must be used, which are both mo... more

Download (79)

View PDF (907)

Effectiveness of Education and an Antibiotic-Control Program in a Tertiary Care Hospital in Thailand

Apisarnthanarak A.,S. Danchaivijitr,T. Khawcharoenporn, et al. (2006) C2

Overuse of antimicrobial agents occurs globally in both community and hospital settings. Misuse of antibiotics can lead to a variety of adverse outcomes, including the development of antimicrobial resistanceand increased cost of hospitalization. This issuehas been particularly problematic in de... more

Download (85)

View PDF (111)

Infection prevention and control in the household management of people with suspected or confirmed coronavirus disease (COVID-19)

European Centre for Disease Prevention and Control ECDC (2020) C1

This document provides guidance on infection prevention and control (IPC) measures for people with suspected or confirmed coronavirus disease (COVID-19) who are experiencing mild symptoms that do not require hospitalisation, therefore self-isolating at home.

Download (68)

View PDF (851)

WHO COVID-19 Detailled Surveillance Data Dashboard
recommended

World Health Organization WHO (2021) C_WHO

Over 18 months into the pandemic, WHO continues to conductglobal surveillance of COVID-19as part of activities on preparedness, readiness and response activities. The need for global surveillance of COVID-19 is greater than ever, asthe implementation of vaccination campaigns and the appearance of va... more

Download (77)

View PDF (992)

Emergency Triage Assessment and Treatment (ETAT) Module

National Newborn Health Program (NNHP), Ministry of Health and Family Welfare Bangladesh (2019) CC

Over a period of two decades, under-5 mortality rate in Bangladesh has declined by 66% from 133 per 1000 live births in 1993-94 to 45 per 1000 live births in 2017-18. The country reached the MDG-4 goal in the reduction of child mortality on time. However, the comparison of neonatal and under-5 morta... more

Download (71)

View PDF (762)

SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021

Kleynhans, J.; et al. (2021) C_CDC

EID Journal , Volume 27, no.12 , Dec. 2021. Early Release Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections may be underestimated because of limited access to testing. We measured SARS-CoV-2 seroprevalence in South Africa every 2 months during July 2020–March 2021 in randoml... more

Download (97)

View PDF (121)

Strategy to Achieve Global Covid-19 Vaccination by mid-2022

World Health Organisation (WHO) (2021) C_WHO

Every country has been affected by COVID-19, with nearly a quarter of a billion cases and almost 5 million deaths reported globally as of end of September 2021. Despite the stunning speed with which highly effective and safe vaccines have been developed, new waves of disease are still pushin... more

Download (163)

View PDF (229)

Monkeypox Case Report Form (CRF) (Arabic)

World Health Organization WHO (2022) C_WHO

21 July 2022. The Rapid Core CRF is designed to collect data obtained through examination, interview and review of hospital or clinic notes of patients with suspected, probable, or confirmed monkeypox infection. Data may be collected prospectively or retrospectively. The data collection period is ... more

Download (77)

View PDF (370)

Infection de plaies dans la pratique clinique: Principes des bonnes pratiques

International Wound Infection Institute (2022) CC

L’infection d’une plaie demeure problématique pour les personnes présentant une plaie, leur famille et les professionnels de santé. L’infection d’une plaie peut entraîner un retard de la cicatrisation, de multiples visites aux services de soins et une durée d’hospitalisation accrue. ... more

Download (100)

View PDF (123)

Clinical management of COVID-19: living guideline, 13 January 2023

World Health Organisation (WHO) (2023) C_WHO

As of 12 December 2022, over 645 million people worldwide have been diagnosed with COVID-19, with over 6.6 million deaths (4). The Omicron variant, which emerged in late November 2021, and its subvariants, are now the dominant circulating viruses, contributing to the ongoing surge in several countr... more

Download (141)

View PDF (143)

Mental health, human rights and legislation: Guidance and practice

UN Office of the High Commissioner for Human Rights OHCHR, World Health Organization WHO (2023) C_WHO

WHO-OHCHR launch new guidance to improve laws addressing human rights abuses in mental health care Ahead of World Mental Health Day, the World Health Organization (WHO) and the Office of the High Commissioner on Human Rights (OHCHR) are jointly launching a new guidance, entitled "Mental health, h... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (20)

View PDF (18)

National Essential Medicines List - Tertiary/Quaternary Medication Review Process

Republic of South Africa (2017) CC

Long Acting Muscarinic Antagonists (LAMA) such as tiotropium and glycopyrronium are used in the management of COPD1. They have been shown to improve lung function, quality of life and exercise tolerance. They have also been associated with reduced COPD-related exacerbations, associated hospitalisati... more

Download (6)

View PDF (7)

Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review

Iheanacho, I.; Zhang, S.; King, D.; et al. International Journal of Chronic Obstructive Pulmonary Disease (2022) CC2

The article "Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review" examines the financial impact associated with moderate-to-very severe COPD. The review analyzes studies published between 2006 and 2016 that discuss healthcare resource utilization (HRU), di... more

Download (30)

View PDF (26)

The Burden of Pediatric Asthma

Ferrante, G.; La Grutta, S. Frontiers in Pediatrics (2018) CC

Asthma is the most common chronic disease in children, imposing a consistent burden on health system. In recent years, prevalence of asthma symptoms became globally increased in children and adolescents, particularly in Low-Middle Income Countries (LMICs). Host (genetics, atopy) and environmental fa... more

Download (27)

View PDF (30)

TENOR risk score predicts healthcare in adults with severe or difficult-to-treat asthma

Miller, M. K.; Lee, J.H.; Blanc, P.D.; et al. (2006) CC2

The aim of the present study was to predict which patients with severe or difficult-to-treat asthma are at highest risk for healthcare utilisation can be predicted so as to optimise clinical management. Data were derived from 2,821 adults with asthma enrolled in The Epidemiology and Natural History ... more

Download (20)

View PDF (19)

Access to essential respiratory medications remains elusive in LMICs

Karmali, D.; Siddharthan, T. (2022) CC

Over 90% of the morbidity and mortality related to chronic obstructive pulmonary disease (COPD) and asthma occurs in low-income and middle-income countries (LMICs) due to well documented factors including decreased access to screening, trained health professionals, and therapies for disease manageme... more

Download (27)

View PDF (15)

Prevention of Allergy and Allergic Asthma

World Health Organization WHO; World Allergy Organization-IAACI (WAO) (2002) CC2

The prevalance of asthma an allergy, defined as immunologically mediated hypersensitivity, is increasing. It is estimated that over 20% of the world population suffers from IgE-mediated allergic disease, such as allergic asthma, allergic rhinitis and allergic conjunctivitis, atopic eczema/atopic der... more

WHO COVID-19 Detailled Surveillance Data Dashboard recommended

WHO COVID-19 Detailled Surveillance Data Dashboard
recommended